ASH 2018 | Role of persistent MRD in MM and elderly AML using next-generation flow
Bruno Paiva
• 4 Dec 2018
Bruno Paiva, PhD, of the University of Navarra, Pamplona, Spain, gives us the updates from his group’s work on measurable residual disease (MRD) in multiple myeloma and elderly acute myeloid leukemia. This work looked at the clinical significance of persistent MRD, as measured by next-generation flow cytometry, of these patients with both standard- and high-risk disease. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
